ASX · AVR.AX
Anteris Technologies Ltd
A$8.83+A$0.28 (+3.27%)
Anteris Technologies Ltd’s quoted price sits in the lower half of its reported 52-week range, 42.92% below the high.
Loading market information…
ASX · BOT.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:12 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Botanix Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 93.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Botanix Pharmaceuticals Limited’s forward annual dividend is A$191.70 per share, paid semi-annual. The forward yield is 1,916,972.4% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Botanix Pharmaceuticals Limited’s next earnings report is currently expected on Mar 3, 2027, with estimated earnings per share of -A$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Botanix Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2024 | Feb 26, 2024 | -A$0.00 | A$377.93K |
|---|
| Q4 2023 | Oct 31, 2023 | -A$0.00 | A$526.98K |
|---|
| Q2 2023 | Feb 28, 2023 | -A$0.00 | A$388.00K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$8.83+A$0.28 (+3.27%)
Anteris Technologies Ltd’s quoted price sits in the lower half of its reported 52-week range, 42.92% below the high.
A$0.72A$0.00 (0.0%)
Monash IVF Group Limited’s quoted price sits in the lower half of its reported 52-week range, 19.55% below the high.
A$0.55+A$0.02 (+2.8%)
Aroa Biosurgery Limited’s quoted price sits in the lower half of its reported 52-week range, 31.25% below the high.
A$0.04-A$0.00 (-2.33%)
Actinogen Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
A$0.55+A$0.02 (+2.8%)
Orthocell Limited’s quoted price sits in the lower half of its reported 52-week range, 56.18% below the high.
A$0.21-A$0.01 (-2.33%)
Dimerix Limited’s quoted price sits in the lower half of its reported 52-week range, 68.42% below the high.
A$0.46-A$0.03 (-6.12%)
Nyrada Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.06% below the high.
A$0.36+A$0.03 (+9.09%)
Recce Pharmaceuticals Ltd’s quoted price sits in the lower half of its reported 52-week range, 50.68% below the high.
